APLS
Apellis Pharmaceuticals Inc
3.40$
-0.1%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -158.1% | -153.2% | -66.9% | -77.2% | -4.2% | 17.3% | 9.1% | -32.0% | 2.5% | 23.7% | -7.1% | -22.7% | 3.4% | |
| 0.4% | 0.4% | 0.3% | 0.3% | 0.2% | 0.2% | 0.2% | 0.3% | 0.2% | 0.1% | -0.6% | 0.1% | 0.0% | |
| 30.8% | 19.6% | 17.9% | 17.6% | 15.0% | 14.0% | 12.4% | 16.4% | 15.2% | 6.1% | -41.4% | 9.4% | -0.2% | |
| 37.6% | – | – | – | – | – | – | – | – | – | – | – | – | |
| -67.7% | -52.1% | -29.1% | -60.1% | -3.1% | 31.9% | 13.3% | 6.2% | 10.3% | -29.7% | 11.3% | -39.4% | -18.2% | |
| 0.4% | 0.0% | 0.1% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | |
| -0.4% | 0.0% | 0.0% | -0.2% | 0.0% | – | 0.0% | 0.0% | 0.0% | 0.0% | -0.1% | – | – | |
| 1.6% | – | 1.1% | – | – | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | 1.6% | – | – | 1.2% | – | -1.1% | – | – | |
| – | – | – | – | – | 0.0% | 0.0% | – | – | 0.0% | 0.0% | – | – | |
| 1.6% | 5.2% | -2.7% | 62.8% | 21.3% | 1.3% | -1.9% | 0.2% | 3.7% | 0.2% | 0.6% | 0.0% | 0.8% | |
| -156.9% | -148.4% | -69.1% | -14.7% | 17.2% | 18.7% | 6.8% | -31.6% | 6.5% | 23.8% | -6.4% | -22.7% | 4.2% | |
| -158.5% | -153.2% | -66.9% | -77.3% | -4.2% | 17.3% | 9.1% | -32.0% | 2.5% | 23.6% | -7.0% | -22.7% | 3.4% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.